OsteoBiologics Inc.
This article was originally published in Start Up
Executive Summary
Until recently, there were no treatments to replace damaged cartilage. OsteoBiologics Inc., spun out of technology licensed from the University of Texas Health Science Center, has developed a resorbable biopolymer that may stand alone to mechanically replace damaged cartilage, or may serve as a biologically friendly scaffolding for cell therapies and techniques involving growth factors.
You may also be interested in...
Biomaterials: Mechanical Engineering Meets Biology
Start-ups developing man-made surrogates for living processes hope to achieve the alchemy of turning base materials into human tissue.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.